Key figures <\/p>\n
CHF millions <\/p>\n
% change <\/p>\n
January\u2013June <\/p>\n
2026 <\/p>\n
2025 <\/p>\n
At CER1 <\/p>\n
In CHF <\/p>\n
In USD <\/p>\n
Group sales <\/p>\n
30,364 <\/p>\n
30,944 <\/p>\n
6 <\/p>\n
-2 <\/p>\n
8 <\/p>\n
Pharmaceuticals Division <\/p>\n
23,629 <\/p>\n
23,985 <\/p>\n
6 <\/p>\n
-1 <\/p>\n
8 <\/p>\n
Diagnostics Division <\/p>\n
6,735 <\/p>\n
6,959 <\/p>\n
3 <\/p>\n
-3 <\/p>\n
6 <\/p>\n
Core operating profit <\/p>\n
11,856 <\/p>\n
12,010 <\/p>\n
10 <\/p>\n
-1 <\/p>\n
Core EPS \u2013 diluted (CHF) <\/p>\n
10.85 <\/p>\n
11.08 <\/p>\n
9 <\/p>\n
-2 <\/p>\n
IFRS operating profit <\/p>\n
9,671 <\/p>\n
10,330 <\/p>\n
6 <\/p>\n
-6 <\/p>\n
Roche CEO Thomas Schinecker: “Our strong momentum continued in the first half of the year, driven by a 6% sales increase at constant exchange rates and significant positive pipeline development.\u00a0\u00a0 <\/p>\n
We reported positive phase III data for divarasib, reinforcing its potential as a best-in-class therapy in advanced lung cancer. Our regulatory momentum accelerated significantly as the US FDA granted five Priority Reviews: giredestrant in early-stage breast cancer, Enspryng in thyroid eye disease, Tecentriq in colon cancer and Gazyva\/Gazyvaro in two autoimmune kidney diseases. <\/p>\n
In Diagnostics, we reached major milestones with the launch of our transformative, highly cost-effective Axelios 1 sequencing solution, alongside EU CE mark for key diagnostic tests, including the Elecsys pTau217 blood test for Alzheimer’s pathology and the Elecsys IGRA TB blood test, which delivers automated, scalable latent tuberculosis screening to laboratories worldwide. <\/p>\n
Backed by our robust pipeline, we are well-positioned for sustained future growth. We confirm our outlook.” <\/p>\n
Group results
In the first six months of 2026, Roche sales were +6% at CER, -2% when reported in CHF, to CHF 30.4 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates. <\/p>\n
Core operating profit was +10% at CER (-1% in CHF) to CHF 11.9 billion, driven by higher sales and other revenue. Core earnings per share were +9% at CER (-2% in CHF). <\/p>\n
IFRS operating profit was -6% in CHF to CHF 9.7 billion. IFRS diluted earnings per share were -8% in CHF. The IFRS results were impacted by the appreciation of the Swiss franc. <\/p>\n
Sales in the Pharmaceuticals Division were +6% at CER, -1% when reported in CHF, to CHF\u00a023.6\u00a0billion, with our medicines across disease areas continuing their strong growth. <\/p>\n
The top five growth drivers \u2013 Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo \u2013 achieved total sales of CHF 11.0 billion, an increase of 12% at CER, or 4% in CHF, compared to the first six months of 2025. <\/p>\n
Sales of products with expired patents (Avastin, Herceptin, MabThera\/Rituxan, Lucentis and Actemra\/RoActemra) were CHF 2.6 billion, a decrease of 8% at CER, or 15% in CHF, compared to the first six months of 2025. <\/p>\n
In the United States, sales were +6% at CER, -3% when reported in CHF, due to continued growth of Xolair, Hemlibra, Polivy (blood cancer) and Tecentriq. This growth more than compensated for the lower sales of Perjeta (breast cancer) and Kadcyla (breast cancer) as well as the impact of biosimilar erosion on Actemra\/RoActemra (rheumatoid arthritis). <\/p>\n
Sales in Europe were +1% at CER, or -1% when reported in CHF, as demand for Ocrevus, Evrysdi (spinal muscular atrophy) and Phesgo more than offset the impact of lower sales of Actemra\/RoActemra due to biosimilar competition and Perjeta because of the conversion of patients to Phesgo. <\/p>\n
In Japan, sales were +11% at CER, -5% when reported in CHF, mainly due to product supply to third parties, as well as the uptake of Elevidys (Duchenne muscular dystrophy) and continued growth of Lunsumio (blood cancer), Vabysmo and Hemlibra. <\/p>\n
Sales in the International region were +10% at CER, or +4% when reported in CHF, led by Phesgo, Vabysmo, Hemlibra, Ocrevus and Polivy. In China, sales were -9% at CER, or -12% when reported in CHF, due to the base effect of a severe flu season in 2025 on Xofluza sales. <\/p>\n
The Diagnostics Division’s sales were +3% at CER, -3% when reported in CHF, to CHF 6.7\u00a0billion, driven by growth in demand for immunodiagnostic and clinical chemistry products\u00a0 as well as pathology and molecular solutions. This growth more than offset the impact of healthcare pricing reforms in China. <\/p>\n
Sales in the Europe, Middle East and Africa (EMEA) region were +3% at CER, -1% when reported in CHF, driven by higher sales of immunodiagnostic products, the clinical chemistry portfolio and molecular solutions. <\/p>\n
In North America, sales were +8% at CER, -1% when reported in CHF, due to growth across the Core Lab and Pathology Lab customer areas. <\/p>\n
Sales in Asia-Pacific were -5% at CER, or -12% when reported in CHF, mainly due to the healthcare pricing reforms in China, partially offset by growth in demand for clinical chemistry and immunodiagnostic products across the rest of the region. <\/p>\n
In Latin America, sales were +10% at CER, or +5% when reported in CHF. <\/p>\n
Pharmaceuticals: key developments <\/p>\n
Compound <\/p>\n
Milestone <\/p>\n
Regulatory <\/p>\n
Gazyva\/Gazyvaro<\/p>\n
Several autoimmune diseases<\/p>\n
\u00a0 <\/p>\n
FDA grants Priority Review for Roche’s Gazyva\/Gazyvaro for adults with primary membranous nephropathy (pMN)<\/p>\n
The Priority Review decision is based on results from the phase III MAJESTY study, where Gazyva\/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus. <\/p>\n
If approved, Gazyva\/Gazyvaro will be the first FDA-approved therapy for pMN, following global approvals in lupus nephritis and ongoing regulatory filings in systemic lupus erythematosus and idiopathic nephrotic syndrome. <\/p>\n
pMN is a chronic autoimmune disease with no FDA- or EMA-approved therapies to date; when left untreated, up to 30% of patients progress to kidney failure over a period of 10 years. <\/p>\n
More information: Media Release<\/a>, 15 July 2026 <\/p>\n Enspryng<\/p>\n Thyroid eye disease <\/p>\n FDA grants Priority Review for Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)<\/p>\n The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED. <\/p>\n Enspryng has the potential to become the first at-home subcutaneous disease-modifying standard of care for TED. <\/p>\n TED is an autoimmune disease affecting approximately 155 out of every 100,000 people that can lead to facial disfigurement and vision-threatening complications if left untreated. <\/p>\n More information: Media Release<\/a>, 30 June 2026 <\/p>\n Lunsumio and Polivy<\/p>\n Blood cancer <\/p>\n FDA accepts supplemental Biologics License Application for Lunsumio and Polivy combination for relapsed or refractory large B-cell lymphoma (LBCL)<\/p>\n Filing acceptance is based on data from the phase III SUNMO study, where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death. <\/p>\n People with relapsed or refractory LBCL represent a population with one of the highest unmet needs in lymphoma and require timely access to effective therapies. <\/p>\n If approved, this outpatient-ready regimen could enable access to care in the community setting, where most US patients receive treatment. <\/p>\n More information: Media release<\/a>, 18 June 2026 <\/p>\n Tecentriq<\/p>\n Colon cancer <\/p>\n FDA grants Priority Review for Tecentriq for a certain type of stage III colon cancer<\/p>\n Filing acceptance is based on data from the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone. <\/p>\n Nearly one in three patients with stage III colon cancer relapses within five years, highlighting a critical need for new adjuvant treatment options. <\/p>\n If approved, Tecentriq plus chemotherapy could provide a new standard of care for the treatment of stage III dMMR\/MSI-H colon cancer after surgery. <\/p>\n More information: Media Release<\/a>, 11 June 2026 <\/p>\n Giredestrant<\/p>\n Breast cancer <\/p>\n FDA accepts New Drug Application for giredestrant in ER-positive early-stage breast cancer, the first and only oral selective oestrogen receptor degrader with positive phase III results in the curative setting<\/p>\n Filing acceptance, under Priority Review, is based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy. <\/p>\n Giredestrant represents the first significant advance in adjuvant endocrine therapy in over 20 years. <\/p>\n Giredestrant has the potential to become a new standard-of-care in the adjuvant setting; more than 90% of ER-positive breast cancer cases are diagnosed at an early stage (I\u2012III). <\/p>\n The FDA has set a Prescription Drug User Fee Act date of 30 November 2026. <\/p>\n More information: Media Release<\/a>, 2 June 2026 <\/p>\n Phase III, pivotal and other key read-outs <\/p>\n Divarasib<\/p>\n Lung cancer <\/p>\n Divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer<\/p>\n Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer. <\/p>\n Divarasib showed clinically meaningful improvements in progression-free survival compared to approved\u00a0 KRAS G12C inhibitors; no new safety signals were observed. <\/p>\n Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population. <\/p>\n More information: Media Release<\/a>, 2 July 2026 <\/p>\n Fenebrutinib Fenebrutinib significantly reduces relapses versus standard of care to approximately one every 17 years in relapsing multiple sclerosis (RMS)<\/p>\n Late-breaking phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in RMS. <\/p>\n Both studies showed positive trends in reducing disability progression with fenebrutinib compared to teriflunomide. <\/p>\n Fenebrutinib could become a first-in-class BTK inhibitor and the first and only high-efficacy oral medication for both RMS and primary progressive multiple sclerosis (PPMS). <\/p>\n More information: Media Release<\/a>, 22 April 2026 <\/p>\n Other <\/p>\n Alzheimer’s integrated portfolio presentation <\/p>\n Roche presents new data on Alzheimer’s disease from across its integrated pharmaceuticals and diagnostics portfolio at AAIC<\/p>\n Five oral presentations in a featured research session highlighted trontinemab, including new long-term data from the phase Ib\/IIa Brainshuttle AD study and the design of phase III PrevenTRON study in preclinical Alzheimer’s disease. <\/p>\n New data on Roche’s CE-marked Elecsys pTau217 blood test were presented on its use for the diagnosis of Alzheimer’s disease in both primary and secondary care. <\/p>\n More information: Media Release<\/a>, 7 July 2026 <\/p>\n Nurix Therapeutics collaboration <\/p>\n Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology<\/p>\n Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies. <\/p>\n Collaboration adds to Roche’s oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis). <\/p>\n Bexobrutideg utilises a novel approach to eliminate the Bruton’s tyrosine kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors. <\/p>\n More information: Media Release<\/a>, 8 June 2026 <\/p>\n Obesity portfolio data presentation <\/p>\n Roche presents new data advancing its obesity portfolio at the American Diabetes Association’s 2026 scientific sessions<\/p>\n Late-breaking phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity. <\/p>\n Late-breaking data from the phase II ZUPREME-1 trial showcase petrelintide’s efficacy, safety and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity. <\/p>\n A phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated in the coming months to develop a differentiated treatment option. <\/p>\n More information: Media Release<\/a>, 1 June 2026 <\/p>\n Oncology portfolio data presentation <\/p>\n Roche presents new data at ASCO 2026, reinforcing giredestrant’s potential to transform the treatment paradigm in early breast cancer<\/p>\n New data were presented from the lidERA study on giredestrant’s potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages. <\/p>\n Primary results were presented from the persevERA study on the numerical improvement in progression-free survival observed with first-line giredestrant plus palbociclib in advanced, endocrine-sensitive disease. <\/p>\n Overall, Roche highlighted data on nine approved and investigational medicines \u2013 including bispecific antibodies, antibody-drug conjugates and brain-permeable molecules \u2013 that target urgent needs in breast, blood, lung and other cancers. <\/p>\n More information: Media Release<\/a>, 19 May 2026 <\/p>\n Ophthalmology portfolio data presentation <\/p>\n Roche presents extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026<\/p>\n New real-world data confirm the potent retinal drying of Vabysmo in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME). <\/p>\n Key data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing treatment burden. <\/p>\n Roche presented more than 45 abstracts at ARVO 2026, including 20 oral presentations across five retinal conditions. <\/p>\n More information: Media Release<\/a>, 30 April 2026 <\/p>\n Pharmaceuticals sales <\/p>\n Sales <\/p>\n CHF millions <\/p>\n As % of sales <\/p>\n % change <\/p>\n January\u2013June <\/p>\n 2026 <\/p>\n 2025 <\/p>\n 2026 <\/p>\n 2025 <\/p>\n At CER <\/p>\n In CHF <\/p>\n Pharmaceuticals Division <\/p>\n 23,629 <\/p>\n 23,985 <\/p>\n 100.0 <\/p>\n 100.0 <\/p>\n 6 <\/p>\n -1 <\/p>\n United States <\/p>\n 12,229 <\/p>\n 12,670 <\/p>\n 51.8 <\/p>\n 52.8 <\/p>\n 6 <\/p>\n -3 <\/p>\n Europe <\/p>\n 4,520 <\/p>\n 4,566 <\/p>\n 19.1 <\/p>\n 19.0 <\/p>\n 1 <\/p>\n -1 <\/p>\n Japan <\/p>\n 1,360 <\/p>\n 1,425 <\/p>\n 5.8 <\/p>\n 5.9 <\/p>\n 11 <\/p>\n -5 <\/p>\n International <\/p>\n 5,520 <\/p>\n 5,324 <\/p>\n 23.3 <\/p>\n 22.3 <\/p>\n 10 <\/p>\n 4 <\/p>\n International: Asia-Pacific, CEETRIS (Central Eastern Europe, T\u00fcrkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n Top 20 best-selling pharmaceuticals <\/p>\n Total <\/p>\n United States <\/p>\n Europe <\/p>\n Japan <\/p>\n International <\/p>\n CHF m <\/p>\n % <\/p>\n CHF m <\/p>\n % <\/p>\n CHF m <\/p>\n % <\/p>\n CHF m <\/p>\n % <\/p>\n CHF m <\/p>\n % <\/p>\n Ocrevus 3,470 <\/p>\n 7 <\/p>\n 2,300 <\/p>\n 2 <\/p>\n 758 <\/p>\n 10 <\/p>\n – <\/p>\n – <\/p>\n 412 <\/p>\n 30 <\/p>\n Hemlibra 2,492 <\/p>\n 11 <\/p>\n 1,313 <\/p>\n 9 <\/p>\n 502 <\/p>\n 4 <\/p>\n 171 <\/p>\n 9 <\/p>\n 506 <\/p>\n 26 <\/p>\n Vabysmo 2,059 <\/p>\n 8 <\/p>\n 1,333 <\/p>\n 1 <\/p>\n 386 <\/p>\n 5 <\/p>\n 75 <\/p>\n 26 <\/p>\n 265 <\/p>\n 65 <\/p>\n Tecentriq 1,704 <\/p>\n 6 <\/p>\n 815 <\/p>\n 9 <\/p>\n 410 <\/p>\n -3 <\/p>\n 146 <\/p>\n -2 <\/p>\n 333 <\/p>\n 17 <\/p>\n Xolair3 1,673 <\/p>\n 27 <\/p>\n 1,673 <\/p>\n 27 <\/p>\n – <\/p>\n – <\/p>\n – <\/p>\n – <\/p>\n – <\/p>\n – <\/p>\n Perjeta3 1,389 <\/p>\n -7 <\/p>\n 551 <\/p>\n -11 <\/p>\n 238 <\/p>\n -14 <\/p>\n 24 <\/p>\n -23 <\/p>\n 576 <\/p>\n 0 <\/p>\n Phesgo 1,318 <\/p>\n 18 <\/p>\n 318 <\/p>\n 0 <\/p>\n 425 <\/p>\n 9 <\/p>\n 88 <\/p>\n 15 <\/p>\n 487 <\/p>\n 47 <\/p>\n Actemra\/RoActemra3 1,074 <\/p>\n -9 <\/p>\n 515 <\/p>\n -9 <\/p>\n 238 <\/p>\n -21 <\/p>\n 140 <\/p>\n 8 <\/p>\n 181 <\/p>\n -3 <\/p>\n Evrysdi 968 <\/p>\n 17 <\/p>\n 323 <\/p>\n 15 <\/p>\n 335 <\/p>\n 17 <\/p>\n 39 <\/p>\n -1 <\/p>\n 271 <\/p>\n 25 <\/p>\n Kadcyla3 916 <\/p>\n -6 <\/p>\n 310 <\/p>\n -14 <\/p>\n 248 <\/p>\n -4 <\/p>\n 39 <\/p>\n 2 <\/p>\n 319 <\/p>\n 3 <\/p>\n Polivy 808 <\/p>\n 20 <\/p>\n 381 <\/p>\n 28 <\/p>\n 128 <\/p>\n -18 <\/p>\n 98 <\/p>\n 16 <\/p>\n 201 <\/p>\n 47 <\/p>\n Alecensa 795 <\/p>\n 6 <\/p>\n 261 <\/p>\n 4 <\/p>\n 126 <\/p>\n -4 <\/p>\n 93 <\/p>\n 8 <\/p>\n 315 <\/p>\n 13 <\/p>\n MabThera\/Rituxan3 609 <\/p>\n 5 <\/p>\n 402 <\/p>\n 14 <\/p>\n 62 <\/p>\n -9 <\/p>\n 6 <\/p>\n -11 <\/p>\n 139 <\/p>\n -10 <\/p>\n Activase\/TNKase3 555 <\/p>\n 11 <\/p>\n 531 <\/p>\n 11 <\/p>\n – <\/p>\n – <\/p>\n – <\/p>\n – <\/p>\n 24 <\/p>\n 12 <\/p>\n Gazyva\/Gazyvaro3 489 <\/p>\n 7 <\/p>\n 240 <\/p>\n 4 <\/p>\n 117 <\/p>\n -1 <\/p>\n 17 <\/p>\n 14 <\/p>\n 115 <\/p>\n 21 <\/p>\n Herceptin3 462 <\/p>\n -12 <\/p>\n 94 <\/p>\n -14 <\/p>\n 136 <\/p>\n -7 <\/p>\n 2 <\/p>\n -36 <\/p>\n 230 <\/p>\n -14 <\/p>\n Avastin3 414 <\/p>\n -15 <\/p>\n 125 <\/p>\n -12 <\/p>\n 35 <\/p>\n 37 <\/p>\n 36 <\/p>\n -44 <\/p>\n 218 <\/p>\n -13 <\/p>\n Pulmozyme3 204 <\/p>\n -8 <\/p>\n 145 <\/p>\n -5 <\/p>\n 29 <\/p>\n -11 <\/p>\n – <\/p>\n 26 <\/p>\n 30 <\/p>\n -18 <\/p>\n Columvi 196 <\/p>\n 70 <\/p>\n 91 <\/p>\n 28 <\/p>\n 53 <\/p>\n 116 <\/p>\n – <\/p>\n – <\/p>\n 52 <\/p>\n 173 <\/p>\n Enspryng 195 <\/p>\n 22 <\/p>\n 50 <\/p>\n 20 <\/p>\n 23 <\/p>\n 20 <\/p>\n 79 <\/p>\n 18 <\/p>\n 43 <\/p>\n 37 <\/p>\n DME: diabetic macular edema \/ nAMD: neovascular or ‘wet’ age-related macular degeneration \/ RVO: retinal vein occlusion \/ RA: rheumatoid arthritis <\/p>\n Diagnostics:\u00a0key developments <\/p>\n Product <\/p>\n Milestone <\/p>\n cobas HDV test <\/p>\n Roche introduces cobas hepatitis D virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis<\/p>\n The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response. <\/p>\n Hepatitis D affects nearly 12 million people globally and is considered the most aggressive form of viral hepatitis, often leading to liver failure and cancer faster than other types. <\/p>\n The cobas HDV test is the first high-throughput, fully automated HDV assay on the market, addressing the urgent need for a consistent, widely accessible solution and expanding access to critical testing just as new treatments for the disease become available. <\/p>\n More information: Media Release<\/a>, 14 July 2026 <\/p>\n Elecsys IGRA TB test <\/p>\n Roche receives CE mark for blood test to identify tuberculosis infection<\/p>\n The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress towards the World Health Organization’s elimination targets. <\/p>\n Performed on Roche’s industry-leading and widely available cobas immunoassay systems, the test enables laboratories to meet growing tuberculosis infection testing needs by reducing reliance on manual workflows through automation and digital solutions. <\/p>\n The new solution provides rapid, high-throughput and cost-effective tuberculosis testing, delivers reliable results in under 24 hours and cuts standard processing times in half to just 19 minutes per patient. <\/p>\n More information: Media Release<\/a>, 9 July 2026 <\/p>\n Axelios 1 sequencing platform <\/p>\n Roche announces the launch of Axelios 1, a transformative next-generation sequencing platform<\/p>\n Axelios 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications. <\/p>\n Powered by innovative SBX technology, the platform is capable of end-to-end, same-day whole-genome sequencing in research workflows, with accurate results within hours. <\/p>\n The Axelios 1 platform holds promise for research laboratories today, and potentially for a broad range of clinical settings in the future. <\/p>\n More information: Media Release<\/a>, 29 June 2026 <\/p>\n Ventana PTEN (SP218) RxDx Assay <\/p>\n Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer<\/p>\n The new Ventana PTEN (SP218) RxDx Assay fulfills an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with Truqap. <\/p>\n In prostate cancer, PTEN protein loss is associated with faster disease progression and reduced benefit from current standard-of-care treatments. <\/p>\n The FDA approval reinforces Roche’s leadership in companion diagnostics and its ongoing commitment to expanding personalised healthcare to improve patient outcomes. <\/p>\n More information: Media Release<\/a>, 12 June 2026 <\/p>\n Liver Disease Panel <\/p>\n Roche launches the Liver Disease Panel, the first suite of certified algorithms to support chronic liver disease (CLD) management<\/p>\n Roche introduces the first comprehensive library of certified healthcare algorithms to support CLD management. <\/p>\n The Liver Disease Panel includes LiverPRO \u2014 a certified algorithm developed by the health tech company Evido \u2014 requiring only age and routine blood markers for the timely detection of liver fibrosis. <\/p>\n With CLD affecting 1.5 billion people worldwide, the non-invasive panel solution covers care along the patient pathway from fibrosis risk identification to the surveillance of liver cancer. <\/p>\n More information: Media Release<\/a>, 27 May 2026 <\/p>\n Elecsys pTau217 test <\/p>\n Roche receives CE mark for new blood test to detect Alzheimer’s pathology: Elecsys plasma phosphorylated-tau 217 (pTau217)<\/p>\n Elecsys pTau217 is the first blood test for Alzheimer’s disease pathology with a single\u2011assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering faster diagnosis for millions of patients around the world. <\/p>\n While maintaining accuracy comparable to spinal fluid diagnostics against the gold standard PET-CT scans, the Elecsys pTau217 test offers a more convenient, minimally invasive alternative via a routine blood draw. <\/p>\n Diagnosing dementia currently takes 3.5 years on average, and an estimated 75% of people living with dementia remain undiagnosed. Elecsys pTau217 offers a simple blood test to aid in earlier, more accessible Alzheimer’s disease diagnosis for millions of patients around the world. <\/p>\n More information: Media Release<\/a>, 12 May 2026 <\/p>\n PathAI agreement <\/p>\n Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics<\/p>\n PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche’s digital pathology portfolio to drive laboratory efficiency. <\/p>\n Combining Roche’s strong position in companion diagnostics and PathAI’s advanced AI platform helps accelerate clinical therapy development, foster the discovery of new biomarkers and create novel diagnostic tools. <\/p>\n These integrated capabilities will accelerate the shift from broad intervention towards personalised healthcare for patients. <\/p>\n
Multiple sclerosis <\/p>\n
Multiple sclerosis <\/p>\n
Haemophilia A <\/p>\n
Eye diseases (nAMD, DME, RVO) <\/p>\n
Cancer immunotherapy <\/p>\n
Chronic hives, food allergies <\/p>\n
Breast cancer <\/p>\n
Breast cancer <\/p>\n
RA, COVID-19 <\/p>\n
Spinal muscular atrophy <\/p>\n
Breast cancer <\/p>\n
Blood cancer <\/p>\n
Lung cancer <\/p>\n
Blood cancer, RA <\/p>\n
Cardiac diseases <\/p>\n
Blood cancer, lupus nephritis <\/p>\n
Breast and gastric cancer <\/p>\n
Various cancer types <\/p>\n
Cystic fibrosis <\/p>\n
Blood cancer <\/p>\n
Acute inflammation of brain, spinal cord and optic nerves <\/p>\n